ANVISA authorizes Dompé's REPAVID-19, a Phase II COVID-19 trial

2 September 2020

Brazil's health regulatory agency, ANVISA, has greenlighted privately-held Italian biopharma company Dompé's REPAVID-19, a clinical trial of reparixin for treatment of severe COVID-19 patients.

Reparixin inhibits the action of interleukin 8 (IL-8), one of the inflammatory signaling proteins that is thought to be associated with the lung injury seen in patients with SARS-CoV2 infection. Consequently, this action is aimed to be useful in the treatment of COVID-19 pneumonia patients. The treatment is based on reparixin oral tablets 1200mg TID till 21 days, in case of confirmed improvement after seven days.

REPAVID-19 will enroll 48 for Phase II, 111 for Phase III with severe COVID-19 pneumonia randomized 2:1 in the Phase II, and the results will inform the study design for the Phase III. The study involves a minimum of 10 Brazilian centers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK